Simulations Plus, Inc. (NASDAQ:SLP) is one of the top 10 medical AI companies to buy according to analysts. On July 29, the ...

Researchers from the Germans Trias i Pujol Research Institute (IGTP) have published a study in Scientific Reports that ...

Researchers from the Cancer Genetics and Epigenetics group at IGTP have published a study in Scientific Reports presenting a ...

Certara, Inc., a global leader in biosimulation, today announced that the European Medicines Agency (EMA) has formally qualified the Simcyp® Simulator for use in regulatory submissions across the EU.

This review explores how generative AI, through models like VAEs, GANs, transformers, and diffusion networks is ...

A professor at the Indiana Univesity Luddy School of Informatics, Computing and Engineering has co-authored a paper ...

The modelling and simulation research team at the NRC's Automotive and Surface Transportation Research Centre is a leader in ...

Total joint replacements have transformed millions of lives, but their success demands rigorous assessment of long-term safety, durability, and performance.

Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications ...

Conestoga Capital Advisors, an asset management company, released its second-quarter 2025 investor letter. A copy of the ...

Complete Response Letters recently issued by the FDA signal heightened scrutiny of trial design and reinforce the agency’s shifting regulatory expectations for sponsors and CROs.

Insiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...